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Sampling Time Is Important but May
Be Overlooked in Establishment and
Use of Thyroid-Stimulating Hormone
Reference Intervals
To the Editor:
In the current debate on reference
interval(s) for serum thyroid-stim-
ulating hormone (TSH) concentra-
tions, a lowering of the upper ref-
erence limit from 4.0 to 2.5, or
even 2.0, mU/L has been proposed
by the National Academy of Clini-
cal Biochemistry (NABC) (1 ). This
proposal is based in part on the
observation that populations with
the lowest prevalence of antithy-
roid antibodies have the lowest
TSH upper limits. Other arguments
for the lowering of the upper limit
of the reference interval are re-
lated to the question of whether
mild TSH increases have any clini-
cal consequences. This question,
however, illustrates the problem of
mixing the concepts of (a) decision
limits (e.g., discrimination values,
cutoffs, action limits), which are
based on the clinical consequences
and treatment strategies and (b)
reference intervals, which are based
solely on biology and mathematics
applied in an appropriate reference
population. This confusion is also
addressed in a recent paper on TSH
reference interval(s) (2 ).
The debate for lowering the up-
per TSH reference limit also in-
cludes the argument that the refer-
ence distribution for serum TSH
should be gaussian in nature, but
the upper tail of the distribution is
currently skewed by: (a) euthyroid
outliers such as may occur in pa-
tients recovering from nonthyroidal
illness, (b) measurement of bioinac-
tive TSH isoforms, (c) TSH receptor
gene polymorphisms, and (d) occult
autoimmune thyroid dysfunction. As
a consequence, some authorities sug-
gest the distribution tail to be de-
leted (1 ). In our opinion, however,
this upper tail is an essential part of
the distribution. In fact, when all
values from individuals at risk are
removed, log-gaussian distributions
are common for most serum compo-
nents (3 ), as we demonstrated for
serum TSH, which is unimodal and
log-gaussian (4 ).
We now focus on the newer docu-
mentation regarding serum TSH ref-
erence intervals and methods. De-
spite the fact that several publications
suggest an upper limit of 4 mU/L,
NACB proposes an upper limit of 2.5
mU/L, although only one of several
population-based studies supports
this (Table 1).
As evidenced in Table 1, studies
vary widely in time of sampling
and analytical methods used, as
well as inclusion and exclusion cri-
teria. The study with the highest
relative median serum TSH in the
DeutschenGesellschaft fu¨rKlinische
Chemie und Laboratoriumsmedi-
zin hormone survey could have
been expected to demonstrate the
highest upper reference limit, but
clearly it does not (Table 1), sug-
gesting that factors other than
method standardization play a
role. Repeated data from external
quality assessment performed
from 2000 to 2005 disclose that be-
tween-method variation is only a
minor source of the variation in
serum TSH. The exclusion of indi-
viduals at risk, however, has been
based on nonstandardized criteria,
and the importance of time of sam-
pling has been ignored. In fact, in
the majority of publications the time of
sampling has not been specified.
There is evidence of a considerable
diurnal variation in serum TSH con-
centration, with a maximum around
midnight (6 ). A decrease of up to
50% occurs from 8:00 to 9:30 AM;
thereafter the concentration remains
relatively constant until evening,
with a smaller nadir in the late after-
noon. Because serum TSH concentra-
tion decreases markedly during the
morning and time of sampling is
unknown in most studies, sampling
time differences between studies
may be a primary reason for the
discrepancies in published reference
intervals. Individuals working night
shifts have displaced or reduced di-
urnal rhythms, a phenomenon that
Table 1. Data from recently published studies on TSH reference intervals.
Publication
Time of blood
sampling
Reference
interval
Sample size
Exclusion
due to:
TSH methods
DGKL Quality
Assessmenta
n
Excluded,
%
Antibodies,
% US
Relative
median CV, % n
Canaris et al. (7 ) ? 0.30–5.10 25 862 0 0 No London diagnostics
Hollowell et al. (8 ) ? 0.45–4.12 17 353 23.1 14.0 No Nichols
Jensen et al. (4 ) 0800–0900 0.58–4.07 1441 31.6 17.3 No AutoDELFIA 0.97 4.4 22
Kratzsch et al. (9 ) 0800–1800 0.40–3.77 870 47.9 22.6 Yes Elecsys 1.00 4.6 22
Völzke et al. (10) ? 0.25–2.12 4298 65.4 3.5 Yes Byk Sangtec 1.12 3.5 16
Eskelinen et al. (11) 0800–1000 0.47–5.60 1252 35.9 22.0 No AutoDELFIA 0.97 4.4 22
d’Herbomez et al. (12) ? 0.35–3.48 763 6.9 6.9 No Access 0.92 4.3 14
Surks et al. (13) ? 0.45–4.17 17 353 17.4 14.0 No Nichols
Hoogedorn et al. (14) 0800–2000 0.34–4.66 6434 19.7 13.9 No Architect 0.87 4.7 22
a In the Deutschen Gesellschaft für KlinischeChemie und Laboratoriumsmedizin (DGKL) hormone survey (5 ) 2 samples (concentrations 1–20 mU/L) were dispatched
1 to 4 times per year during 2000 to 2005. The Nichols test is not used in Europe. Byk Sangtec is used by very few. Exclusion US relates to morphological alterations
by ultrasound. Eskelinen et al. (12), studied only in individuals 65 years. US, ultrasound.
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should also be acknowledged (or
such individuals excluded) when es-
tablishing reference intervals. Conse-
quently, our proposal is to establish
reference intervals as a function of
time of sampling to reveal the influ-
ence of time on reference limits for
serum TSH. The outcome of sam-
pling time investigations will indicate
whether such data will lead to recom-
mendations for time of sampling or to
time-dependent reference intervals.
Studies to establish decision limits
for serum TSH should be based on
standardized measurements per-
formed in longitudinal follow-up of
cohorts with various concentrations of
serum TSH. Such studies may well sup-
port intervention below a serum TSH
concentration of 4.0 mU/L. At present,
however, such a decision is not based
on unequivocal evidence (2).
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A Combinatorial Haplotype of the
UDP-Glucuronosyltransferase 1A1
Gene (#60-#IB) Increases Total
Bilirubin Concentrations in Japanese
Volunteers
To the Editor:
UDP-glucuronosyltransferases (UGTs)
are a family of enzymes that glucu-
ronidate many endogenous and exog-
enous substrates (1). Of the UGT1A
gene isoforms, UGT1A1 is primarily
responsible for glucuronidation of
bilirubin (1). In east Asians, 2 well-
known genetic variants, A(TA)6TAA
A(TA)7TAA (allele *28, reduced tran-
scription) and G71R (211GA, allele
*6, reduced activity), are causative fac-
tors for increased plasma bilirubin
concentrations in Gilbert syndrome
(1). The *28 allele is almost always
linked to the *60 allele (-3279TG),
with reduced in vitro transcription (2).
In a previous study (2 ) in which
we divided UGT1A1 into 2 haplo-
type blocks (the 5-flanking region
and exon 1 in block 1 and common
exons 2 to 5 in block 2), *60 and *IB
(perfectly linked 1813CT, 1941CG,
and 2042CG in the 3-untranslated
region in Japanese persons) showed
increased total bilirubin concentra-
tions in non-*28 patients. Because of
the small number of patients, how-
ever, it was not clear whether biliru-
bin concentrations were affected by
*60 and *IB acting independently
or cooperatively when they were on
the same chromosome. To clarify
this point, we reinvestigated the as-
sociations between the UGT1A1 hap-
lotypes and total bilirubin concen-
trations in 554 healthy Japanese
volunteers. The ethical review boards
of the participating institutions ap-
proved this study, and informed
consent was obtained from
all participants.
For genotyping of *60, *28, *6, and
*IB marker variations, DNA was ex-
tracted from Epstein-Barr-virus–
transformed lymphoblastoid cells.
The genotyping methods for the *60,
*6, and *IB alleles were described
previously (3, 4). For *IB, 1941CG
was genotyped (3). For *28,364CT,
which is perfectly linked with the *28
allele in Japanese persons (2), was
used as a surrogate polymorphism,
as described in Fig. 1 in the Data
Supplement that accompanies the on-
line version of this Letter at http:
//www.clinchem.org/content/vol53/
issue2, which also shows the allele
frequencies of the variations. The dip-
lotype configuration (combination of
haplotypes) for each volunteer was
inferred by an expectation-maximiza-
tion–based program, LDSUPPORT, as
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